Onward Medical Future Growth
Future criteria checks 2/6
Onward Medical's earnings are forecast to decline at 1.3% per annum while its annual revenue is expected to grow at 113.9% per year. EPS is expected to grow by 8.2% per annum.
Key information
-1.3%
Earnings growth rate
8.2%
EPS growth rate
| Medical Equipment earnings growth | 15.7% |
| Revenue growth rate | 113.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 39 | -33 | -34 | -31 | 3 |
| 12/31/2025 | 10 | -44 | -38 | -43 | 4 |
| 12/31/2024 | 2 | -36 | -34 | -36 | 4 |
| 6/30/2024 | 0 | -35 | -29 | -29 | N/A |
| 3/31/2024 | 0 | -36 | -31 | -30 | N/A |
| 12/31/2023 | 1 | -36 | -33 | -32 | N/A |
| 9/30/2023 | 1 | -36 | -33 | -33 | N/A |
| 6/30/2023 | 2 | -36 | -33 | -33 | N/A |
| 3/31/2023 | 2 | -34 | -30 | -30 | N/A |
| 12/31/2022 | 2 | -33 | -27 | -27 | N/A |
| 9/30/2022 | 2 | -35 | -27 | -26 | N/A |
| 6/30/2022 | 2 | -38 | -27 | -25 | N/A |
| 3/31/2022 | 2 | -36 | -25 | -22 | N/A |
| 12/31/2021 | 1 | -34 | -22 | -20 | N/A |
| 9/30/2021 | 1 | -29 | -18 | -17 | N/A |
| 6/30/2021 | 1 | -24 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -22 | -13 | -13 | N/A |
| 12/31/2020 | 1 | -20 | -13 | -13 | N/A |
| 12/31/2019 | 1 | -13 | -10 | -10 | N/A |
| 12/31/2018 | 0 | -10 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 63E is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 63E is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 63E is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 63E's revenue (113.9% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 63E's revenue (113.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 63E's Return on Equity is forecast to be high in 3 years time